Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

News > Health News

Audio By Carbonatix

8:05 AM on Tuesday, February 10

The Associated Press

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Feb 10, 2026--

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on February 24, 2026, at 8:30 a.m. ET to discuss the results.

To participate in the call, please dial 800-274-7083 (domestic) or 203-518-9786 (international), and reference passcode HRMYQ425. It is recommended that you dial in at least 10 minutes prior to the call.

The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences

Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260210287847/en/

CONTACT: Investor Contact:

Matthew Beck

astr partners

917-415-1750

[email protected] Contact:

Cate McCanless

Harmony Biosciences

202-641-6086

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA PENNSYLVANIA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH